…
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Tandem Diabetes Care designs and sells insulin pumps, software and related diabetes-management systems for people with insulin-dependent diabetes, operating in the medical devices and digital health industry. Long-term growth may be supported by rising AID (automated insulin delivery) adoption, ongoing integration with continuous glucose monitors, software-upgrade revenue and international expansion, which could support continued market share gains.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -92.85M | 15.90M | -36.28M | -24.60M | -122.56M |
| Net income | -94.59M | 15.57M | -34.38M | -24.75M | -122.61M |
| Selling general administrative | 335.68M | 261.51M | 204.90M | 165.74M | 105.23M |
| Gross profit | 412.99M | 376.21M | 260.52M | 194.21M | 89.82M |
| Reconciled depreciation | 14.33M | 13.85M | 10.45M | 6.07M | 5.82M |
| Ebit | -61.81M | 8.81M | -18.41M | -22.79M | -50.45M |
| Ebitda | -30.77M | 22.65M | -7.96M | -16.72M | -44.63M |
| Depreciation and amortization | 31.04M | 13.85M | 10.45M | 6.07M | 5.82M |
| Non operating income net other | -0.00M | -6.75M | -28.32M | -7.88M | -77.93M |
| Operating income | -61.81M | 8.81M | -7.96M | -16.72M | -44.63M |
| Other operating expenses | 863.03M | 680.15M | 506.79M | 379.03M | 228.50M |
| Interest expense | 4.31M | 4.31M | 12.15M | 0.08M | 7.58M |
| Tax provision | 1.74M | 0.34M | -1.90M | 0.15M | 0.05M |
| Interest income | 6.06M | 0.67M | 1.57M | 3.27M | 1.46M |
| Net interest income | -0.15M | -5.37M | -11.24M | 3.19M | -6.12M |
| Non recurring | 31.04M | - | - | - | - |
| Income tax expense | 1.74M | 0.34M | -1.90M | 0.15M | 0.05M |
| Total revenue | 801.22M | 702.80M | 498.83M | 362.31M | 183.87M |
| Total operating expenses | 474.80M | 353.56M | 268.48M | 210.93M | 134.45M |
| Cost of revenue | 388.23M | 326.58M | 238.31M | 168.09M | 94.04M |
| Total other income expense net | -31.04M | 7.09M | -28.32M | -7.88M | -77.93M |
| Net income from continuing ops | -94.59M | 15.57M | -34.38M | -24.75M | -122.61M |
| Net income applicable to common shares | -94.59M | 15.57M | -34.38M | -24.75M | -122.61M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 967.66M | 952.66M | 1052.79M | 905.14M | 716.41M |
| Intangible assets | 0.93M | 2.78M | 4.63M | 6.64M | 8.80M |
| Other current assets | 21.96M | 16.59M | 7.24M | 8.43M | 6.38M |
| Total liab | 704.56M | 639.03M | 612.84M | 472.02M | 350.11M |
| Total stockholder equity | 263.10M | 313.63M | 439.95M | 433.11M | 366.31M |
| Other current liab | 149.82M | 84.62M | 77.60M | 84.36M | 70.54M |
| Common stock | 0.07M | 0.07M | 0.07M | 0.06M | 0.06M |
| Capital stock | 0.07M | 0.07M | 0.07M | 0.06M | 0.06M |
| Retained earnings | -1047.83M | -951.80M | -729.19M | -634.60M | -659.21M |
| Other liab | - | - | 36.09M | 34.78M | 27.36M |
| Other assets | - | - | 10.70M | 9.09M | 29.16M |
| Cash | 69.23M | 58.87M | 172.52M | 71.18M | 94.61M |
| Total current liabilities | 247.05M | 195.26M | 165.29M | 131.86M | 103.85M |
| Current deferred revenue | 11.83M | 43.99M | 18.84M | 10.18M | 6.08M |
| Net debt | 404.33M | 356.80M | 247.36M | 243.49M | 133.71M |
| Short term debt | 40.67M | 17.06M | 13.12M | 9.28M | 9.42M |
| Short long term debt | 40.67M | - | - | - | - |
| Short long term debt total | 473.56M | 415.67M | 419.88M | 314.67M | 228.32M |
| Other stockholder equity | 1312.80M | 1264.00M | 1170.89M | 1068.26M | 1025.23M |
| Property plant equipment | - | - | 68.55M | 50.39M | 50.02M |
| Total current assets | 724.49M | 747.99M | 849.98M | 811.52M | 637.24M |
| Long term investments | 74.55M | - | - | - | - |
| Net tangible assets | - | - | 439.95M | 433.11M | 366.31M |
| Short term investments | 369.10M | 409.04M | 444.38M | 552.63M | 390.32M |
| Net receivables | 114.58M | 105.56M | 114.72M | 110.72M | 82.19M |
| Long term debt | 308.27M | 285.04M | 283.23M | 281.47M | 202.98M |
| Inventory | 149.61M | 157.94M | 111.12M | 68.55M | 63.72M |
| Accounts payable | 44.73M | 49.59M | 55.73M | 28.03M | 17.80M |
| Accumulated other comprehensive income | -1.95M | 1.37M | -1.82M | -0.62M | 0.22M |
| Common stock total equity | - | - | 0.07M | 0.06M | 14.26M |
| Retained earnings total equity | - | - | -729.19M | -634.60M | -659.21M |
| Non currrent assets other | 4.24M | 37.56M | 19.00M | 9.09M | 0.58M |
| Non current assets total | 243.17M | 204.67M | 202.81M | 93.62M | 79.18M |
| Capital lease obligations | 124.63M | 130.63M | 136.65M | 33.20M | 25.34M |
| Long term debt total | - | - | - | 281.47M | 202.98M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 33.17M | -163.37M | -263.76M | -37.41M | -87.75M |
| Change to liabilities | 13.10M | 33.73M | 12.88M | 28.90M | 17.87M |
| Total cashflows from investing activities | 33.17M | -186.88M | -296.06M | -56.95M | -90.74M |
| Net borrowings | - | - | 278.69M | 278.69M | -87.71M |
| Total cash from financing activities | 16.88M | 51.93M | 314.44M | 24.21M | 117.18M |
| Change to operating activities | 12.78M | 29.42M | 9.46M | 18.82M | 13.84M |
| Net income | -94.59M | 15.57M | -34.38M | -24.75M | -122.61M |
| Change in cash | 101.34M | -23.43M | 43.44M | 9.35M | 18.13M |
| Begin period cash flow | 71.18M | 94.61M | 51.17M | 41.83M | 23.70M |
| End period cash flow | 172.52M | 71.18M | 94.61M | 51.17M | 41.83M |
| Total cash from operating activities | 50.46M | 111.36M | 24.67M | 41.91M | -8.32M |
| Issuance of capital stock | - | - | 0.00M | 0.00M | 172.93M |
| Depreciation | 14.33M | 13.85M | 10.45M | 6.07M | 5.82M |
| Other cashflows from investing activities | -34.58M | -9.33M | -4.89M | -37.41M | -87.75M |
| Change to inventory | -42.45M | -4.95M | -15.36M | -30.98M | 6.76M |
| Change to account receivables | -7.83M | -30.98M | -38.84M | -13.70M | -15.85M |
| Sale purchase of stock | 17.55M | 51.93M | 69.82M | 24.21M | 31.97M |
| Other cashflows from financing activities | -0.59M | 0.59M | 247.57M | 0.33M | 31.97M |
| Change to netincome | 121.73M | 65.48M | 76.39M | 73.50M | 97.75M |
| Capital expenditures | 42.95M | 23.51M | 32.29M | 19.54M | 2.99M |
| Change receivables | -7.83M | -30.98M | -38.84M | -13.70M | -15.85M |
| Cash flows other operating | 40.10M | 16.57M | 4.73M | 3.42M | -0.31M |
| Cash and cash equivalents changes | 100.51M | -23.59M | 43.05M | 9.16M | 18.13M |
| Change in working capital | -4.65M | 14.37M | -36.59M | -12.35M | 8.46M |
| Stock based compensation | 84.92M | 60.75M | 58.43M | 58.07M | 23.74M |
| Other non cash items | 50.46M | 2.27M | 28.88M | -0.32M | 76.27M |
| Free cash flow | 7.51M | 87.85M | -7.62M | 22.36M | -11.30M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care Inc |
-0.89 4.74% |
17.88 | - | 1111.11 | 1.56 | 9.90 | 1.69 | -10.72 |
| ABT Abbott Laboratories |
-0.71 0.65% |
108.58 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
0.28 0.28% |
101.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-2.16 0.68% |
316.63 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
47.31 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
12400 High Bluff Drive, San Diego, CA, United States, 92130
858 366 6900
2650
| Name | Title | Year Born |
|---|---|---|
| Mr. John F. Sheridan | Pres, CEO & Director | 1955 |
| Ms. Leigh A. Vosseller | Exec. VP, CFO & Treasurer | 1973 |
| Mr. David B. Berger Esq. | Exec. VP & COO | 1970 |
| Ms. Susan M. Morrison | Exec. VP & Chief Admin. Officer | 1979 |
| Mr. Brian B. Hansen | Exec. VP & Chief Commercial Officer | 1968 |
| Ms. Elizabeth Anne Gasser | Exec. VP & Chief Strategy Officer | 1976 |
| Mr. Rick A. Carpenter | Chief Technical Officer | 1963 |
| Ms. Shannon M. Hansen | Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. | 1966 |
| Mr. Ross Sylvia | VP of Marketing | NA |
| Mr. Tom Fox | Sr. VP of HR & Organizational Devel. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.